Concord Wealth Partners Stoke Therapeutics, Inc. Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 500 shares of STOK stock, worth $6,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$6,550% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
135Shares Held
60MCall Options Held
5.6KPut Options Held
142K-
Skorpios Trust6.91MShares$90.5 Million99.7% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$70.9 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.29MShares$69.3 Million13.01% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$67.1 Million0.56% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$60.7 Million0.37% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $516M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...